LIMN
Liminatus Pharma, Inc. Class A Common Stock (LIMN) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Negative TTM ROIC indicates capital is not yet compounding efficiently, but the near-zero cash conversion cycle suggests working-capital discipline relative to more cash-intensive peers.
Net debt to EBITDA is low at 0.13x, which gives LIMN more balance-sheet flexibility than leveraged peers and reduces refinancing pressure.
Current and quick ratios of 1.12x indicate short-term liquidity is adequate, supporting operational continuity better than peers with sub-1.0x coverage.
Weaknesses
TTM ROIC of -2.25% shows the business is destroying value on invested capital, leaving LIMN structurally weaker than profitable peers.
Debt to equity of 4.80x signals a highly levered capital structure, which constrains strategic flexibility versus peers with lower balance-sheet risk.
Liquidity is only modest at 1.12x current and quick ratios, so LIMN has less cushion than stronger peers if working capital tightens.
The absence of disclosed operating and gross margin data limits evidence of durable unit economics, while peers with clearer margin strength appear better positioned.
Opportunities
If LIMN converts its low net leverage into growth investment, it can scale faster than debt-constrained peers without immediate balance-sheet stress.
Improving ROIC from negative territory would materially narrow the gap versus peers and could re-rate the business if capital allocation discipline improves.
Stable liquidity provides room to simplify operations and strengthen cash generation, which could improve competitive positioning against peers with tighter funding.
Threats
Persistent negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest more aggressively and widen the performance gap.
High debt-to-equity increases vulnerability to earnings volatility, making LIMN more exposed than lower-leverage peers if financing conditions tighten.
With only moderate liquidity, any slowdown in collections or margin pressure could force defensive actions sooner than for better-capitalized peers.
Overall Score
LIMN’s structural profile is कमजोर versus peers because negative capital returns and high leverage outweigh its modest liquidity and low net debt.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Liminatus Pharma, Inc. Class A Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.